ProCE Banner Activity

Subgroup Analyses and Overall HRQoL From Phase III TAGS: Trifluridine/Tipiracil vs Placebo in Previously Treated Gastric/GEJ Adenocarcinoma

Slideset Download
Conference Coverage
Survival outcomes with trifluridine/tipiracil in patients aged ≥ 65 years or those with metastatic GEJ cancer were generally consistent with the overall patient population, and HRQoL outcomes were stable over time in the overall population.

Released: June 11, 2019

Expiration: June 09, 2020

No longer available for credit.

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro